Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Oncolys BioPharma receives 'conformity' notification for OBP-301 document review and GCP inspection
Oncolys BioPharma Inc. <4588> announced after the close of trading on the 3rd that it has received a notification of 'conformity' from the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the conformity document review and GCP on-site inspection for its oncolytic virus OBP-301 targeting esophageal cancer, for which it filed a marketing authorization application in December last year. The company plans to begin sales of OBP-301 from the fiscal year ending December 2026 after obtaining marketing authorization from the Minister of Health, Labour and Welfare.
Source: MINKABU PRESS
Related Articles
Next Week's Market Outlook: Will April Foreign Buying Materialize Amid Iran Tensions?
Forex Market Outlook: Middle East Tensions to Continue Driving Currency Movements
ZUIKO Projects 5.2x Surge in Ordinary Profit, \8 Dividend Increase for Feb 2027 Term on Strong Domestic and China Demand
HODEN SEIMITSU KAKO KENKYUSHO's FY Feb 2026 Swings to Net Profit Growth, Raises Dividend Forecast by \3
Space Development Ranks 11th as Artemis Program's Successful Crewed Launch Draws Attention
Tokyo Stocks Close \660 Higher on Tech Rally; Semiconductor Shares Attract Buying
TSI HOLDINGS Reports FY Feb 2026 Results Below Guidance
eXmotion's Q1 Operating Profit Rises 55%
Key Market Events for the Week Ahead
Active Stocks (Close, April 3): SAKURA internet, NPC Inc, Shinko Shoji and Others